RDD has an unpredictable clinical course and is fatal in 5–10% of cases, and thus, MAPK/RAF inhibitors have been used to treat RDD given the frequency of MEK pathway mutations. This evidence concerns the gene MAP2K7 and sinus histiocytosis with massive lymphadenopathy.